CTIS2023-508030-33-00进行中（未招募）1 期
BEX17850
Sanofi-Aventis Recherche & Developpement0 个研究点目标入组 13 人开始时间: 2024年1月9日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 13
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A study in healthy male adult participants to assess how much test medicine (SAR443820) is taken up, broken down and removed by the body when given in a liquid form by mouth.amyotrophic lateral sclerosis (ALS)MedDRA version: 21.1Level: PTClassification code: 10002026Term: Amyotrophic lateral sclerosis Class: 100000004852CTIS2022-502534-23-00Sanofi-Aventis Research & Development6
进行中（未招募）
1 期
A Phase I study to evaluate the pharmacokinetics, safety and tolerability of multiple oral doses of obefazimod in participants with renal impairment and matched normal kidney function.Moderately to severely active ulcerative colitisCTIS2024-514561-20-00Abivax48
招募中
1 期
A study to investigate the effects of multiple doses of obefazimod on a combined oral contraceptive (ethinyl estradiol/drospirenone) in healthy female participants of childbearing potential.Healthy female participants of childbearing potential.MedDRA version: 21.1Level: LLTClassification code: 10003268Term: Arthritis rheumatoid Class: 10028395MedDRA version: 20.1Level: PTClassification code: 10021972Term: Inflammatory bowel disease Class: 100000004856CTIS2023-505297-15-00Abivax36
招募中
1 期
A Phase 1, 2-part, open-label, single-sequence study to investigate the effect of single and multiple doses of obefazimod on the pharmacokinetics of rosuvastatin in healthy male participants.Moderately to severely active ulcerative colitisMedDRA version: 20.0Level: PTClassification code: 10009900Term: Colitis ulcerative Class: 100000004856CTIS2023-509226-21-00Abivax24
进行中（未招募）
1 期
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease ParticipantsAlzheimer’s DiseaseMedDRA version: 20.0Level: LLTClassification code: 10001896Term: Alzheimer's disease Class: 10029205CTIS2024-514004-14-00ovartis Pharma AG25